FindTrial
Sign In

Holmium-166 radioembolization

DEVICE3 trials

Sponsors

UMC Utrecht, Universitair Ziekenhuis Brussel

Conditions

Hepatocellular CarcinomaHepatocellular Carcinoma Non-resectableLiver CirrhosisLocally Advanced Hepatocellular CarcinomaNon-metastatic Hepatocellular Carcinoma

Phase 2

HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients
CompletedNCT03379844
UMC UtrechtHepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable
Start: 2017-08-21End: 2021-08-01Updated: 2022-11-08

Unknown Phase

Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma
NCT05114148
UMC UtrechtHepatocellular Carcinoma Non-resectable
Start: 2022-03-01End: 2025-11-01Target: 30Updated: 2022-11-10
Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma
RecruitingNCT06873269
Universitair Ziekenhuis BrusselLiver Cirrhosis, Locally Advanced Hepatocellular Carcinoma, Non-metastatic Hepatocellular Carcinoma
Start: 2025-02-01End: 2026-02-01Target: 100Updated: 2025-03-12

Related Papers

Hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with 166Ho-radioembolization
EJNMMI Research2025-01-092 citations
Holmium-166 radioembolisation dosimetry in HCC
European Journal of Nuclear Medicine and Molecular Imaging2024-10-297 citations
Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment delivery
European Journal of Nuclear Medicine and Molecular Imaging2022-07-1320 citations